Bavarian Nordic Upgrades Full-Year 2026 Financial Guidance After Strong Travel Health Performance

Bavarian Nordic upgraded its 2026 financial guidance, raising Travel Health revenue expectations to approximately DKK 3,400 million from DKK 3,000 million, driven by stronger-than-expected rabies vaccine sales in the United States amid increased animal rabies activity. Total 2026 revenue is now projected at approximately DKK 6,100 million with an EBITDA margin of approximately 32%, up from previous guidance of 30%.